Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:20 p.m.

    📋 Editas Medicine, Inc. (EDIT) - Financial Results

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 06:46:59

    Event Type: Financial Results

    Event Details:

    Editas Medicine Inc (EDIT) Reports Q3 2022 Financial Results Editas Medicine Inc (EDIT) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 68888
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 527620
      • “Since joining Editas Medicine two months ago, my review of the innovative technologies, strong CMC capabilities, and talented team has reinforced my enthusiasm about the company’s potential. I see tremendous value in our technology and ability to develop novel medicines, and I intend to focus our efforts on transforming the business from a technology platform company into a therapeutics company,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “In addition, I’m excited to welcome our new Chief Medical Officer, Dr. Baisong Mei, to the leadership team, where he will utilize his deep experience in developing therapeutics from pre
      • clinical stages through global approvals to assist in this transformation.”Recent Achievements and OutlookEx Vivo Gene Edited Medicines●EDIT
      • 301 for Sickle Cell Disease​First SCD patient treated with EDIT

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Other Income Net Total Other Income Expense -1.00 1.00 $-2.00 -200.00%
    Other Income Net Net Loss -55.26K -103.97K $48.71K +46.85%
    Cash Equivalents Marketable Securities 527.62K 527.62K $0.00 +0.00%
    Revenue 6.36K 6.36K $0.00 +0.00%
    Interest Income 546.00 546.00 $0.00 +0.00%
    Other Income, Net 781.00 781.00 $0.00 +0.00%
    Net Loss -53.45K -53.45K $0.00 +0.00%
    Cash and Marketable Securities 527.62K 527.62K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Editas Medicine Inc
    • CIK: 0001650664
    • Ticker Symbol: EDIT
    • Period End Date: 2022-08-03
    • Document Type: 8-K

Search

News categories